Maxim Group analyst Naz Rahman maintained a Buy rating on Cingulate Inc (CING – Research Report) yesterday and set a price target of $3.00. The company’s shares opened today at $0.96.
According to TipRanks, Rahman is an analyst with an average return of -37.2% and a 17.65% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Agile Therapeutics, 9 Meters Biopharma, and Viking Therapeutics.
Cingulate Inc has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $4.40 and a one-year low of $0.66. Currently, Cingulate Inc has an average volume of 53.09K.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.
Read More on CING:
- Cingulate Benzinga All Live Access Appearance Rescheduled for December 16
- Cingulate to Participate in Benzinga All Live Access Event
- Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
- Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD
- Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update
